Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 2 | 2024 | 73 | 1.720 |
Why?
|
| Blood Coagulation Disorders | 2 | 2024 | 25 | 1.100 |
Why?
|
| Antifibrinolytic Agents | 2 | 2024 | 22 | 1.090 |
Why?
|
| Coronary Artery Bypass | 2 | 2024 | 68 | 1.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2024 | 15 | 0.900 |
Why?
|
| Thrombophilia | 1 | 2024 | 10 | 0.900 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 68 | 0.880 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2023 | 40 | 0.820 |
Why?
|
| Platelet Function Tests | 1 | 2022 | 24 | 0.820 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 104 | 0.820 |
Why?
|
| Brain Ischemia | 1 | 2023 | 82 | 0.780 |
Why?
|
| Cognition | 1 | 2024 | 298 | 0.720 |
Why?
|
| Humans | 36 | 2024 | 27121 | 0.690 |
Why?
|
| Internship and Residency | 1 | 2023 | 228 | 0.680 |
Why?
|
| Stroke | 1 | 2023 | 241 | 0.660 |
Why?
|
| Postoperative Complications | 1 | 2024 | 605 | 0.650 |
Why?
|
| Thrombelastography | 3 | 2024 | 46 | 0.630 |
Why?
|
| Blood Transfusion | 3 | 2024 | 73 | 0.620 |
Why?
|
| Acetaminophen | 1 | 2015 | 11 | 0.490 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2015 | 8 | 0.490 |
Why?
|
| Medication Errors | 1 | 2015 | 26 | 0.480 |
Why?
|
| Neuromuscular Blockade | 2 | 2024 | 8 | 0.460 |
Why?
|
| Ambulances | 1 | 2013 | 12 | 0.440 |
Why?
|
| Patient Transfer | 1 | 2013 | 42 | 0.430 |
Why?
|
| Risk Assessment | 3 | 2024 | 595 | 0.420 |
Why?
|
| General Surgery | 1 | 2013 | 53 | 0.420 |
Why?
|
| Thrombosis | 2 | 2023 | 147 | 0.380 |
Why?
|
| Anesthesia | 2 | 2024 | 25 | 0.340 |
Why?
|
| Macular Degeneration | 1 | 2011 | 79 | 0.340 |
Why?
|
| Intensive Care Units | 2 | 2024 | 46 | 0.340 |
Why?
|
| Fibrinolysin | 3 | 2024 | 15 | 0.330 |
Why?
|
| Indians, North American | 2 | 2011 | 514 | 0.330 |
Why?
|
| Thrombin | 3 | 2024 | 68 | 0.330 |
Why?
|
| Mass Media | 1 | 2009 | 8 | 0.320 |
Why?
|
| Parent-Child Relations | 1 | 2009 | 70 | 0.310 |
Why?
|
| Smoking Prevention | 1 | 2009 | 87 | 0.300 |
Why?
|
| Blood Loss, Surgical | 2 | 2024 | 52 | 0.270 |
Why?
|
| Hemostasis | 2 | 2024 | 47 | 0.270 |
Why?
|
| Risk Factors | 4 | 2024 | 2030 | 0.270 |
Why?
|
| Keratoconjunctivitis | 1 | 2006 | 4 | 0.260 |
Why?
|
| Eye Infections, Viral | 1 | 2006 | 5 | 0.260 |
Why?
|
| Adenovirus Infections, Human | 1 | 2006 | 8 | 0.260 |
Why?
|
| Hospitals, Special | 1 | 2006 | 3 | 0.260 |
Why?
|
| Adenoviridae | 1 | 2006 | 66 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2023 | 2454 | 0.250 |
Why?
|
| Blood Coagulation | 2 | 2024 | 116 | 0.250 |
Why?
|
| Cross Infection | 1 | 2006 | 35 | 0.250 |
Why?
|
| Aconitine | 1 | 2024 | 1 | 0.240 |
Why?
|
| Anesthesiologists | 1 | 2024 | 4 | 0.240 |
Why?
|
| Treatment Outcome | 4 | 2024 | 2283 | 0.230 |
Why?
|
| Tranexamic Acid | 1 | 2024 | 13 | 0.230 |
Why?
|
| Renal Dialysis | 1 | 2024 | 52 | 0.230 |
Why?
|
| Urea | 1 | 2024 | 16 | 0.230 |
Why?
|
| Critical Care | 1 | 2024 | 48 | 0.230 |
Why?
|
| Postpartum Hemorrhage | 1 | 2024 | 9 | 0.230 |
Why?
|
| Blood Coagulation Tests | 1 | 2024 | 27 | 0.220 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 46 | 0.220 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 65 | 0.220 |
Why?
|
| Aminocaproic Acid | 1 | 2023 | 6 | 0.220 |
Why?
|
| Liver Transplantation | 1 | 2024 | 52 | 0.220 |
Why?
|
| Hemodilution | 1 | 2023 | 9 | 0.210 |
Why?
|
| Work Schedule Tolerance | 1 | 2023 | 10 | 0.210 |
Why?
|
| Electronic Health Records | 1 | 2024 | 60 | 0.210 |
Why?
|
| Medicine | 1 | 2023 | 22 | 0.210 |
Why?
|
| Hemostatics | 1 | 2023 | 18 | 0.210 |
Why?
|
| Sex Characteristics | 1 | 2024 | 163 | 0.210 |
Why?
|
| Platelet Transfusion | 1 | 2023 | 29 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 68 | 0.200 |
Why?
|
| Surgeons | 1 | 2023 | 49 | 0.200 |
Why?
|
| Spine | 1 | 2022 | 60 | 0.200 |
Why?
|
| Male | 9 | 2015 | 13022 | 0.190 |
Why?
|
| Phylogeny | 1 | 2024 | 462 | 0.190 |
Why?
|
| Ophthalmology | 2 | 2012 | 36 | 0.190 |
Why?
|
| Quality of Health Care | 2 | 2012 | 78 | 0.190 |
Why?
|
| Hemorrhage | 1 | 2023 | 260 | 0.190 |
Why?
|
| Aged | 6 | 2024 | 5222 | 0.180 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 133 | 0.180 |
Why?
|
| Child | 4 | 2014 | 2160 | 0.180 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 171 | 0.180 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 213 | 0.180 |
Why?
|
| Aged, 80 and over | 4 | 2013 | 1940 | 0.170 |
Why?
|
| Adolescent | 4 | 2014 | 2988 | 0.170 |
Why?
|
| Female | 9 | 2024 | 14636 | 0.160 |
Why?
|
| Oklahoma | 3 | 2014 | 978 | 0.160 |
Why?
|
| Prevalence | 2 | 2011 | 478 | 0.150 |
Why?
|
| Middle Aged | 5 | 2013 | 6900 | 0.140 |
Why?
|
| Patient Positioning | 1 | 2017 | 22 | 0.140 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2008 | 5 | 0.140 |
Why?
|
| Conjunctival Neoplasms | 2 | 2008 | 6 | 0.140 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2017 | 26 | 0.140 |
Why?
|
| Eye Neoplasms | 2 | 2008 | 7 | 0.140 |
Why?
|
| Neural Tube Defects | 1 | 2017 | 20 | 0.140 |
Why?
|
| Corneal Diseases | 2 | 2008 | 21 | 0.130 |
Why?
|
| Time Factors | 2 | 2013 | 1570 | 0.130 |
Why?
|
| Health Priorities | 1 | 2014 | 7 | 0.120 |
Why?
|
| Public Health Administration | 1 | 2014 | 15 | 0.120 |
Why?
|
| Community Mental Health Services | 1 | 2014 | 15 | 0.120 |
Why?
|
| Intubation, Intratracheal | 1 | 2014 | 26 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2014 | 31 | 0.120 |
Why?
|
| Uncertainty | 1 | 2014 | 23 | 0.110 |
Why?
|
| New Zealand | 1 | 2013 | 10 | 0.110 |
Why?
|
| Logistic Models | 2 | 2014 | 398 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2014 | 1100 | 0.110 |
Why?
|
| Health Education | 1 | 2014 | 71 | 0.110 |
Why?
|
| Parents | 1 | 2014 | 122 | 0.110 |
Why?
|
| Anxiety | 1 | 2014 | 140 | 0.100 |
Why?
|
| Mandatory Reporting | 1 | 2012 | 5 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 62 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 175 | 0.100 |
Why?
|
| Sunlight | 1 | 2011 | 10 | 0.090 |
Why?
|
| Vitamins | 1 | 2011 | 22 | 0.090 |
Why?
|
| Keratitis, Herpetic | 1 | 2010 | 4 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 58 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 160 | 0.090 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 64 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 658 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2010 | 930 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2010 | 35 | 0.090 |
Why?
|
| Ophthalmologic Surgical Procedures | 2 | 2008 | 23 | 0.090 |
Why?
|
| Interferon-alpha | 2 | 2008 | 50 | 0.090 |
Why?
|
| Health Personnel | 1 | 2010 | 91 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2010 | 111 | 0.080 |
Why?
|
| Sex Factors | 1 | 2011 | 452 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 162 | 0.080 |
Why?
|
| Age Factors | 1 | 2011 | 721 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2011 | 863 | 0.080 |
Why?
|
| Hypertension | 1 | 2011 | 305 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 282 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 342 | 0.070 |
Why?
|
| Morpholines | 2 | 2024 | 27 | 0.070 |
Why?
|
| Retina | 1 | 2011 | 422 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 364 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 750 | 0.070 |
Why?
|
| United States | 3 | 2023 | 2060 | 0.070 |
Why?
|
| Young Adult | 1 | 2013 | 2626 | 0.070 |
Why?
|
| Adenoviruses, Human | 1 | 2005 | 21 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 928 | 0.060 |
Why?
|
| Cornea | 1 | 2005 | 65 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2005 | 67 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 133 | 0.060 |
Why?
|
| Smoking | 1 | 2009 | 465 | 0.060 |
Why?
|
| History, 16th Century | 1 | 2024 | 7 | 0.060 |
Why?
|
| History, 17th Century | 1 | 2024 | 7 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 140 | 0.060 |
Why?
|
| Anesthetics | 1 | 2024 | 9 | 0.060 |
Why?
|
| History, 18th Century | 1 | 2024 | 12 | 0.060 |
Why?
|
| History, Medieval | 1 | 2024 | 20 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2005 | 153 | 0.060 |
Why?
|
| History, Ancient | 1 | 2024 | 35 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2024 | 36 | 0.060 |
Why?
|
| Anesthesiology | 1 | 2024 | 18 | 0.060 |
Why?
|
| Neostigmine | 1 | 2024 | 3 | 0.060 |
Why?
|
| Postoperative Hemorrhage | 1 | 2024 | 30 | 0.060 |
Why?
|
| Indicator Dilution Techniques | 1 | 2024 | 7 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2024 | 83 | 0.060 |
Why?
|
| Administration, Topical | 3 | 2010 | 28 | 0.060 |
Why?
|
| Incidence | 1 | 2006 | 553 | 0.060 |
Why?
|
| North America | 1 | 2024 | 39 | 0.060 |
Why?
|
| Blood Component Transfusion | 1 | 2024 | 13 | 0.060 |
Why?
|
| Factor Xa | 1 | 2023 | 13 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2024 | 38 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2024 | 64 | 0.050 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2023 | 8 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 33 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2023 | 28 | 0.050 |
Why?
|
| Factor VIII | 1 | 2023 | 19 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 988 | 0.050 |
Why?
|
| Public Health Practice | 2 | 2014 | 13 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2023 | 36 | 0.050 |
Why?
|
| Factor Xa Inhibitors | 1 | 2023 | 53 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2023 | 50 | 0.050 |
Why?
|
| Research Design | 1 | 2024 | 174 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2023 | 104 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2023 | 113 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2022 | 116 | 0.050 |
Why?
|
| Adult | 3 | 2014 | 7492 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2023 | 293 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 216 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1149 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 608 | 0.040 |
Why?
|
| Obesity | 1 | 2023 | 654 | 0.040 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2017 | 2 | 0.030 |
Why?
|
| Supine Position | 1 | 2017 | 4 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 43 | 0.030 |
Why?
|
| State Government | 1 | 2014 | 18 | 0.030 |
Why?
|
| Nose | 1 | 2014 | 22 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 75 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 53 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 63 | 0.030 |
Why?
|
| Video Recording | 1 | 2014 | 38 | 0.030 |
Why?
|
| Language | 1 | 2014 | 62 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 846 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 397 | 0.030 |
Why?
|
| Documentation | 1 | 2012 | 24 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2014 | 1219 | 0.020 |
Why?
|
| Acyclovir | 1 | 2010 | 8 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 77 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 114 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 141 | 0.020 |
Why?
|
| Registries | 1 | 2011 | 383 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 408 | 0.020 |
Why?
|
| Chromones | 1 | 2005 | 11 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2005 | 21 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2005 | 40 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 31 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2005 | 10 | 0.020 |
Why?
|
| Mitomycin | 1 | 2005 | 19 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2005 | 53 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2005 | 265 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2005 | 187 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 153 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 201 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 290 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 568 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 395 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 977 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 740 | 0.010 |
Why?
|